Legal gems: Supply of S3 naloxone
No Thumbnail Available
File version
Author(s)
Hope, Denise L
Dickfos, Steven T
King, Michelle A
Dickfos, Steven T
King, Michelle A
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2017
Size
File type(s)
Location
License
Abstract
In February 2016, naloxone 400 mcg/mL was rescheduled for supply as a Schedule 3 (S3; Pharmacist Only) medication for the treatment of opioid overdose. For all other purposes, naloxone remains a Schedule 4 (S4; Prescription Only) medication. Until manufacturer packaging is modified to comply with S3 provision, pharmacists are required to amend the packaging and provide additional education/instructions for the safe supply of S3 naloxone.
Journal Title
Australian Pharmacist
Conference Title
Book Title
Edition
Volume
36
Issue
2
Thesis Type
Degree Program
School
DOI
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject
Pharmacology and pharmaceutical sciences
Persistent link to this record
Citation
Hope, DL; Dickfos, ST; King, MA, Legal gems: Supply of S3 naloxone, Australian Pharmacist, 2017, 36 (2), pp. 59-59